The problem with revving up the immune system to fight cancer is that the immune system has never met a gas pedal it didn’t want to floor straight through a retaining wall. That is basically the story of CD137, also called 4-1BB: push it, and CD8 T cells can become much better at killing tumors. Push it too hard, and the liver gets volunteered as tribute.
This new mouse study in Science Advances tackles that exact mess head-on. The short version: the authors found a way to trim the toxic T-cell response without wrecking the antitumor one. In immunotherapy terms, that is catnip. In real life, it is the difference between “interesting biology” and “maybe one day patients can actually use this safely” (Shein et al., 2026).
Why CD137 Keeps Showing Up to the Party
CD137 is a costimulatory receptor on activated T cells. Translation: it is one of the molecules that tells a T cell, “Yes, you absolutely should keep going.” When that signal lands, CD8 T cells tend to proliferate, survive longer, and hit harder. Great for tumors. Less great when the same amped-up immune cells start torching healthy tissue on the side (CD137 on Wikipedia).
That tradeoff has haunted CD137 drug development for years. The field has known this target can work, but the clinical history has also featured a sobering amount of liver toxicity. Which is a very efficient way to ruin everyone’s afternoon (Melero et al., 2023; Liu and Luo, 2023).
The Cells Causing Trouble
The paper zooms in on a specific crowd of effector CD8 T cells marked by CD11c and KLRG1. These cells were pumping out interferon-gamma, a powerful inflammatory signal that is useful right up until it starts acting like a flamethrower in the liver. The authors found that these cells circulate through blood and secondary lymphoid organs, then can pile into the liver and drive hepatotoxicity (Shein et al., 2026; Interferon-gamma on Wikipedia).
The clever bit is what keeps these cells alive. It was not just the T cells freelancing. The study points to lymphotoxin beta receptor, or LTβR, signaling in fibroblastic reticular cells inside lymphoid organs. B cells help feed that pathway. Net effect: these especially inflammatory CD8 cells avoid the usual contraction phase where excess effector cells are supposed to die off like adults leaving a bad group chat.
Block LTβR, and those toxic circulating effector T cells start disappearing on schedule.
The Plot Twist Immunotherapy Needed
Here is the part worth sitting up for. LTβR blockade reduced liver toxicity while preserving tumor-specific CD8 T-cell responses in the mouse models. That is the whole game.
Cancer immunotherapy has a recurring problem: the same biology that helps kill tumors often causes collateral damage elsewhere. It is like hiring the world’s best security team and discovering they also punch through drywall, sprinkler systems, and at least one innocent bystander. This paper suggests you may not need to suppress the whole immune response. You may just need to selectively cull the most reckless circulating effector cells.
That idea fits with where the broader field has been heading. Recent reviews and clinical strategy papers keep circling the same goal: make 4-1BB agonism more tumor-focused and less systemically chaotic, whether through antibody engineering, conditional activation, or smarter combinations (Claus et al., 2023; Liu and Luo, 2023). There is even related evidence that anti-CD137 toxicity can be uncoupled from efficacy by changing the immune context, including the gut microbiota (Blake et al., 2021).
Why This Matters Outside Mouse World
If these findings hold up, the real-world impact could be pretty big. CD137 has always been one of those immunotherapy ideas that makes scientists lean forward and clinicians squint suspiciously. Strong antitumor potential. Awkward tendency to injure the liver. Not ideal.
A strategy that preserves the useful tumor attack while dumping the dangerous spillover could make CD137-based therapies more usable, especially in combinations. And combinations are where this field keeps trying to go. Nobody in oncology has ever seen a promising immune target and thought, “What if we used it calmly and only once?”
That said, brakes on the hype. This is preclinical work in mice. Human immune systems are more annoying, less tidy, and generally unwilling to read the methods section. We also do not know whether LTβR blockade would preserve efficacy across many tumor types, dosing schedules, or combination regimens. Liver toxicity in patients can be biologically messy even with better-established immunotherapies (Cunningham et al., 2024).
Still, this is the kind of paper that earns attention. Not because it promises miracles. Because it takes a very old immunotherapy headache and offers a mechanistic way to separate the good from the bad. In oncology, that counts as a pretty good night.
References
Shein SA, Korchagina AA, Wang LJ, et al. Selective elimination of circulating effector CD8 T cells via LTβR blockade separates anti-CD137 efficacy from toxicity. Science Advances. 2026;12(17):eaea8737. DOI: https://doi.org/10.1126/sciadv.aea8737
Melero I, Sanmamed MF, Glez-Vaz J, et al. CD137 (4-1BB)-Based Cancer Immunotherapy on Its 25th Anniversary. Cancer Discovery. 2023;13(3):552-569. DOI: https://doi.org/10.1158/2159-8290.CD-22-1029
Liu G, Luo P. Targeting CD137 (4-1BB) towards improved safety and efficacy for cancer immunotherapy. Frontiers in Immunology. 2023;14:1208788. DOI: https://doi.org/10.3389/fimmu.2023.1208788
Claus C, Ferrara-Koller C, Klein C. The emerging landscape of novel 4-1BB (CD137) agonistic drugs for cancer immunotherapy. mAbs. 2023;15(1):2167189. DOI: https://doi.org/10.1080/19420862.2023.2167189
Blake SJ, James J, Ryan FJ, et al. The immunotoxicity, but not anti-tumor efficacy, of anti-CD40 and anti-CD137 immunotherapies is dependent on the gut microbiota. Cell Reports Medicine. 2021;2(12):100464. DOI: https://doi.org/10.1016/j.xcrm.2021.100464. PMCID: https://pmc.ncbi.nlm.nih.gov/articles/PMC8714857/
Cunningham M, Gupta R, Butler M. Checkpoint inhibitor hepatotoxicity: pathogenesis and management. Hepatology. 2024;79(1):198-212. DOI: https://doi.org/10.1097/HEP.0000000000000045
Disclaimer: The image accompanying this article is for illustrative purposes only and does not depict actual experimental results, data, or biological mechanisms.